Texas Attorney General Sues Sanofi Over Alleged Kickback Scheme
AUSTIN, TX – Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Sanofi-Aventis U.S. LLC (“Sanofi”), alleging the company engaged in an illegal kickback scheme designed to incentivize healthcare providers to prescribe Sanofi drugs over competing alternatives. The lawsuit, filed on Thursday, February 19, 2026, claims Sanofi created programs offering “free nurse” and “support services” to providers, which the state argues constitute unlawful remuneration under the Texas Health Care Program Fraud Prevention Act (THFPA). This marks the latest legal challenge against Sanofi by Attorney General Paxton, who has previously pursued cases concerning the company’s marketing and disclosure practices.
The core of the lawsuit centers on Sanofi’s alleged efforts to influence prescribing decisions for drugs treating a range of conditions, including diabetes, multiple sclerosis, autoimmune disorders, and hemophilia. According to the Attorney General’s office, these kickbacks established long-term revenue streams for Sanofi, even if the prescribed drugs weren’t the most appropriate treatment option for individual patients. The state contends that the programs were intentionally designed to sway which medications Texans receive, prioritizing Sanofi’s profits over patient well-being.
Details of the Alleged Kickback Scheme
The lawsuit specifically targets Sanofi’s “Free Nurse Program” and “Support Services Program.” These programs reportedly provided nursing services and reimbursement support to healthcare providers. The Attorney General’s office argues that these services acted as in-kind remuneration, effectively rewarding providers for prescribing Sanofi’s medications. According to a press release from the Texas Attorney General’s office, the scheme violated the THFPA, which prohibits such practices.
“The quality of Texans’ healthcare should never be determined by Big Pharma bribery,” stated Attorney General Paxton. “Sanofi is in clear violation of Texas law that prohibits the exact type of kickback scheme that the company is actively engaging in. The people of Texas deserve to know that the drugs they’re being prescribed are being given to them to best address their medical needs.”
Seeking Monetary Relief and an Injunction
The state of Texas is seeking more than $1,000,000 in monetary relief, including civil penalties, as well as an injunction to halt any further unlawful acts by Sanofi. The lawsuit aims to prevent Sanofi from continuing to offer these alleged kickbacks and to ensure that prescribing decisions are based on medical necessity rather than financial incentives. The Attorney General’s office believes that the financial penalties sought will serve as a deterrent to similar practices by other pharmaceutical companies.
Previous Legal Battles with Sanofi
What we have is not the first time Attorney General Paxton has taken legal action against Sanofi. In November 2025, Paxton filed a lawsuit against Sanofi and Bristol-Myers Squibb, alleging they failed to disclose that their drug Plavix was ineffective for certain patients. The lawsuit claimed that the companies knowingly marketed Plavix as effective despite evidence suggesting it had diminished or no effect on patients of Black, East Asian, and Pacific Islander descent. Plavix, a medication intended to prevent heart attacks, strokes, and blood clots, was at the center of the allegations.
Attorney General Paxton has also previously sued Eli Lilly for allegedly providing illegal kickbacks to providers to promote its medications. This pattern of litigation demonstrates Paxton’s commitment to holding pharmaceutical companies accountable for practices he deems harmful to Texans.
Sanofi’s Response
Sanofi has responded to the lawsuit, stating that the programs in question are structured to comply with applicable federal and state laws and are intended to support patients, not influence prescribing decisions. According to Reuters, the company maintains that the state’s intervention has no merit and that it will vigorously defend itself against the allegations. Sanofi asserts that the services provided are legitimate patient support programs and do not constitute illegal kickbacks.
“These services are structured to comply with applicable federal and state laws and are intended to support patients, not to influence prescribing decisions,” Sanofi said in a statement. “The state’s intervention has no impact on the merits of this case, and Sanofi is vigorously defending this lawsuit.”
Broader Implications for the Pharmaceutical Industry
This lawsuit against Sanofi is part of a broader trend of increased scrutiny of pharmaceutical marketing practices and the potential for conflicts of interest. Concerns about the influence of pharmaceutical companies on prescribing decisions have been growing for years, leading to calls for greater transparency and stricter regulations. The case could set a precedent for future legal challenges against other pharmaceutical companies accused of similar practices.
The allegations against Sanofi raise important questions about the ethical responsibilities of pharmaceutical companies and the need to protect patients from potentially biased medical advice. The outcome of this lawsuit could have significant implications for the pharmaceutical industry and the way drugs are marketed and prescribed in Texas and beyond.
What Happens Next?
The lawsuit is currently pending in a Texas court. The next steps will involve Sanofi filing a formal response to the complaint, followed by a period of discovery where both sides gather evidence. A trial date has not yet been set. The Attorney General’s office is expected to present evidence supporting its claims that Sanofi engaged in an illegal kickback scheme, while Sanofi will likely argue that its programs were legitimate patient support initiatives. The case is expected to be closely watched by the pharmaceutical industry and patient advocacy groups.
Readers can find more information about the lawsuit and related documents on the Texas Attorney General’s website: www.texasattorneygeneral.gov.
What are your thoughts on this case? Share your comments below and let us know what you think about the role of pharmaceutical companies and the importance of ethical prescribing practices.
Related reading